ClinicalTrials.gg
CompletedNCT01355458Updated Feb 18, 2021Results posted

Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea

A Phase 3 interventional study of CD07805/47 gel and Placebo in Rosacea, sponsored by Galderma R&D. Completed at 15 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing brimonidine in Rosacea — none open to participants now, none under way, none of them phase 3. brimonidine · Rosacea.

Enrollment
5th of 11
260 · median 205
Started
2011
with 2 others
Phase 3
4 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
8 of 11
Galderma R&D

Among the 11 studies testing brimonidine in Rosacea, this one is the 5th largest by enrollment, is one of 3 that started in 2011, is one of 4 in phase 3, and was the 5th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 11 studies testing brimonidine in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About brimonidine

brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing brimonidine in Rosacea as a file.
02

Study summary

Phase 3 efficacy and safety study of CD07805/47 topical gel in subjects with facial erythema associated with rosacea. The study hypothesis is that CD07805/47 gel, applied topically once daily is more efficacious than vehicle and provides an acceptable safety profile in the treatment of facial erythema associated with rosacea.

03

Conditions studied

  • Rosacea

Browse trials for

Keywords

  • rosacea
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female who is at least 18 years of age or older.
  2. A clinical diagnosis of facial rosacea.
  3. A Clinician Erythema Assessment (CEA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).
  4. A Patient Self Assessment (PSA) score of greater than or equal to 3 at Screening and at Baseline/Day 1 (prior to the study drug application).

Key Exclusion Criteria:

  1. Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, isolated pustulosis of the chin) or other concomitant facial dermatoses that are similar to rosacea such as peri-oral dermatitis, demodicidosis, facial keratosis pilaris, seborrheic dermatitis, acute lupus erythematosus, or actinic telangiectasia.
  2. Presence of three (3) or more facial inflammatory lesions of rosacea.
  3. Current treatment with monoamine oxidase (MAO) inhibitors, barbiturates, opiates, sedatives, systemic anesthetics, or alpha agonists.
  4. Less than 3 months stable dose treatment with tricyclic antidepressants, cardiac glycosides, beta blockers or other antihypertensive agents.
  5. Current diagnosis of Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    CD07805/47 gel

    Drug: CD07805/47 gel

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugCD07805/47 gel

    Drug page: Brimonidine

    applied topically once daily

  • DrugPlacebo

    applied topically once daily

06

What researchers measure

Primary outcomes

  1. Composite Success

    Composite Success is defined as 2-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

    Time frame: Day 29

07

Results

Posted Nov 21, 2013

Participant flow

Participant flow — Overall Study
MilestoneCD07805/47 GelPlacebo
Started129131
Completed127127
Not completed24

Outcome measures

PrimaryComposite Success

Composite Success is defined as 2-grade improvement on both Clinician Erythema Assessment (CEA) and Patient Self Assessment(PSA).

Time frame:
Day 29
Reported as:
Number · participants
Composite Success
participantsCD07805/47 GelPlacebo
Day 29 / Hour 34014
Day 29 / Hour 63912
Day 29 / Hour 93313
Day 29 / Hour 122911
Statistical analysis
  • CD07805/47 Gel vs Placebo · GEE: Logit link function · p = <0.001Generalized Estimating Equation (GEE) methods with Logit link function and marginal expectation model.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CD07805/47 Gel—1/129 (0.8%)0/129 (0%)
Placebo—0/131 (0%)0/131 (0%)
Most frequent serious events
Most frequent serious events
EventCD07805/47 GelPlacebo
Accidental drug intake by childInjury, poisoning and procedural complications1/1290/131

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)CD07805/47 GelPlaceboTotal
<=18 years000
Between 18 and 65 years117117234
>=65 years121426
Age, Continuous
Age, Continuous(years)CD07805/47 GelPlaceboTotal
Mean49.5 ± 11.7648.1 ± 12.8148.8 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)CD07805/47 GelPlaceboTotal
Female104102206
Male252954
Region of Enrollment
Region of Enrollment(participants)CD07805/47 GelPlaceboTotal
United States115116231
Canada141529
08

Study locations

15 sites
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • University of California, San Francisco
    San Francisco, California 94143, United States
  • Michigan Center for Skin Care Research
    Clinton Township, Michigan 48038, United States
  • Windsor Dermatology
    East Windsor, New Jersey 08520, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Philadelphia Institute of Dermatology
    Fort Washington, Pennsylvania 19034, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37922, United States
  • Arlington Center for Dermatology
    Arlington, Texas 76011, United States
  • DermResearch, Inc.
    Austin, Texas 78759, United States
  • Dermatology Treatment & Research Center
    Dallas, Texas 72230, United States
  • The Education & Research Foundation, Inc.
    Lynchburg, Virginia 24501, United States
  • Lynderm Research Inc
    Markham, Ontario L3P 1A8, Canada
  • Windsor Clinical Research Inc.
    Windsor, Ontario N8W 5L7, Canada
  • Innovaderm Research, Inc
    Montreal, Quebec H2K 4L5, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Sep 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2013, 2 years 2 months after primary completion. A results delay was requested in Jul 2012.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2011
First posted
May 18, 2011
Start
May 2011
Primary completionActual
Sep 2011
CompletionActual
Dec 2011
Results delay requested
Jul 23, 2012
Results first posted
Nov 21, 2013
Last update
Feb 18, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01355458
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
May 18, 2011
Start date
May 2011
Primary completion
Sep 2011
Completion
Dec 2011
Results posted
Nov 21, 2013
Last update
Feb 18, 2021

Study contacts

Michael Graeber, MD
study chair · Galderma R&D
William Abramovits, MD
principal investigator · Dermatology Treatment & Research Center
Robert Bissonette, MD
principal investigator · Innovaderm Research Inc.
Zoe Draelos, MD
principal investigator · Dermatology Consulting Services, High Point NC
Kimberly Grande, MD
principal investigator · The Skin Wellness Center
Michael Jarratt, MD
principal investigator · Derm Research, PLLC
Charles Lynde, MD
principal investigator · Lynderm Research Inc
Robert Matheson, MD
principal investigator · Oregon Medical Research Center
Kappa Meadows, MD
principal investigator · The Education & Research Foundation, Inc.
Angela Moore, MD
principal investigator · Arlington Center for Dermatology
David Nieves, MD
principal investigator · Windsor Dermatology
Andrew Pollack, MD
principal investigator · Philadelphia Institute of Dermatology
Howard Sofen, MD
principal investigator · Dermatology Research Associates
Martin Steinhoff, MD
principal investigator · University of California, San Francisco
Daniel Stewart, DO
principal investigator · Michigan Center for Skin Care Research
Jerry Tan, MD
principal investigator · Windsor Clinical Research Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brimonidine

Start the discussion